Anti-cancer drugs

Keyphrases

Publications

2023

Linping Gu, Yi Zhao, Fengcai Wen, Ding Zhang, Jinping Cai, Zhiwei Chen
A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites. Anti-cancer drugs (2023)
Guijuan Zhang, Xiaoyuan Tang, Xingping Zhang, Xingting Qiu, Qingwen Lai, Jie Li
Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced myocardial damage: a case report and literature review. Anti-cancer drugs (2023)
Urwashi Kumar, Jyotirmoi Aich, Shine Devarajan
Exploring the repurposing potential of telmisartan drug in breast cancer: an in-silico and in-vitro approach. Anti-cancer drugs (2023)
Jinlu Zhao, Guodong Li, Yi Ren, Zhicheng Zhang, Hongsheng Chen, Haopeng Zhang, Xingyu Zhao, Wang Li, Yucheng Jia, Xue Guan, Ming Liu
Ellagic acid inhibits human colon cancer HCT-116 cells by regulating long noncoding RNAs. Anti-cancer drugs (2023)
Bensong Duan, Haibin Zhang, Zhen Zhu, Xiaohan Yan, Zhonghua Ji, Jingze Li
LncRNA LINC01871 sponging miR-142-3p to modulate ZYG11B promotes the chemoresistance of colorectal cancer cells by inducing autophagy. Anti-cancer drugs (2023)
Lavorini Eugenia, Alemanno Giovanni, Mari Andrea, Raspollini Maria Rosaria, Vittori Gianni, Bacchiani Mara, Maltinti Gherardo, Lavacchi Daniele, Antonuzzo Lorenzo, Minervini Andrea, Prosperi Paolo
Mucinous appendiceal adenocarcinoma invading the bladder: not always an easy diagnosis. A case report. Anti-cancer drugs (2023)
Gianluca Ricco, Renata Seminerio, Elisa Andrini, Deborah Malvi, Elisa Gruppioni, Annalisa Altimari, Stefano Zagnoni, Davide Campana, Giuseppe Lamberti
BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: a case report and review of the literature. Anti-cancer drugs (2023)
Guangxin Wang, Xia Gao, Zhijun Sun, Tianyou He, Chaogang Huang, Shouwei Li, Haocheng Long
Circular RNA SMARCA5 inhibits cholangiocarcinoma via microRNA-95-3p/tumor necrosis factor receptor associated factor 3 axis. Anti-cancer drugs (2023)
Reza Haseli, Masoud Honarvar, Kamal Yavari, Mehrdad Ghavami
Synergistic anticancer effects of crocin combined with deuterium-depleted water on HT-29 cells. Anti-cancer drugs (2023)
Moustafa Salaheldin Abdelhamid, Ahmed Fouad El-Farargy, Omnia Abdelhai Esawi
Synthesis and evaluation of novel thiazole moiety-containing compounds as antibreast cancer agents. Anti-cancer drugs (2023)
Zhaofeng Wang, Ranpu Wu, Chuling Li, Kai Cheng, Yicheng Di, Tangfeng Lv, Hongbing Liu, Yong Song
Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review. Anti-cancer drugs (2023)
Wenzhuo Yang, Junliang Ge, Meng Yuan, Jialin Li, Lin Pan, Xiaochuang Wang, Junan Ren, Gaojing Dou, Laiyu Yang, Yang Zhou, Haoqun Xie, Xinhui Wang, Hongrong Hu
Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C. Anti-cancer drugs (2023)
Geena Chacko, Srigowri Kota, Shicha Kumar, Nisha Ohri, Coral Omene, Shridar Ganesan, Deborah L Toppmeyer, Mridula A George
Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer. Anti-cancer drugs (2023)
Xiaojuan Chen, Guoying Jin, Hong Luo, Lifei Zhou
Effect of Gubenyiliu formula II and its disassembled prescriptions on cell autophagy in breast cancer through PI3K/AKT/mTOR pathway. Anti-cancer drugs (2023)

volume 34, number 10, 2023

Elif B Köksoy, Hakan Akbulut
A late relapse thymoma and pure red cell aplasia case with an over 5 years of clinical response under everolimus. Anti-cancer drugs 34 (10) (2023)
Puja Ghosh, Muhasina K M, Neelaxi Pandey, Duraiswamy Basavan
Jackfruit waste: an invented anticancer therapy using Jacalin lectin from jackfruit seed. Anti-cancer drugs 34 (10) (2023)
Melek Tugce Yilmaz, Sezin Yuce Sari, Gozde Yazici
In regard to Cabezas-Camarero et al. Anti-cancer drugs 34 (10) (2023)

volume 34, number 2, 2023

Yan Huang, Yuying Zhang, Yuzhen Zhou, Ying Chen, Qianmeng Zhu
CDKN2B-AS1 is overexpressed in polycystic ovary syndrome and sponges miR-181a to promote granulosa cell proliferation. Anti-cancer drugs 34 (2) (2023)
Bingfeng Guan, Xiaofeng Dai, Yan Zhu, Qing Geng
M2 macrophage-derived exosomal miR-1911-5p promotes cell migration and invasion in lung adenocarcinoma by down-regulating CELF2 -activated ZBTB4 expression. Anti-cancer drugs 34 (2) (2023)
Yan Huang, Yuying Zhang, Yuzhen Zhou, Ying Chen, Qianmeng Zhu
CDKN2B-AS1 is overexpressed in polycystic ovary syndrome and sponges miR-181a to promote granulosa cell proliferation. Anti-cancer drugs 34 (2) (2023)
Fanjie Qu, Xin Yan, Weiwei Yu
Combination toripalimab and bevacizumab for an elderly urothelial carcinoma patient with brain metastasis who failed rapidly after radiotherapy: a case report and literature review. Anti-cancer drugs 34 (2) (2023)
Bingfeng Guan, Xiaofeng Dai, Yan Zhu, Qing Geng
M2 macrophage-derived exosomal miR-1911-5p promotes cell migration and invasion in lung adenocarcinoma by down-regulating CELF2 -activated ZBTB4 expression. Anti-cancer drugs 34 (2) (2023)
Yan Huang, Yuying Zhang, Yuzhen Zhou, Ying Chen, Qianmeng Zhu
CDKN2B-AS1 is overexpressed in polycystic ovary syndrome and sponges miR-181a to promote granulosa cell proliferation. Anti-cancer drugs 34 (2) (2023)
Fanjie Qu, Xin Yan, Weiwei Yu
Combination toripalimab and bevacizumab for an elderly urothelial carcinoma patient with brain metastasis who failed rapidly after radiotherapy: a case report and literature review. Anti-cancer drugs 34 (2) (2023)
Yan Huang, Yuying Zhang, Yuzhen Zhou, Ying Chen, Qianmeng Zhu
CDKN2B-AS1 is overexpressed in polycystic ovary syndrome and sponges miR-181a to promote granulosa cell proliferation. Anti-cancer drugs 34 (2) (2023)
Haipeng Huang, Jiange Zhang, Peng Jiang, Xiaolong Xu, Fu Huang, Binli Zhao, Xiaoming Wang, Liquan Zhou
FXR1 facilitates axitinib resistance in clear cell renal cell carcinoma via regulating KEAP1/Nrf2 signaling pathway. Anti-cancer drugs 34 (2) (2023)
Fanjie Qu, Xin Yan, Weiwei Yu
Combination toripalimab and bevacizumab for an elderly urothelial carcinoma patient with brain metastasis who failed rapidly after radiotherapy: a case report and literature review. Anti-cancer drugs 34 (2) (2023)
Haipeng Huang, Jiange Zhang, Peng Jiang, Xiaolong Xu, Fu Huang, Binli Zhao, Xiaoming Wang, Liquan Zhou
FXR1 facilitates axitinib resistance in clear cell renal cell carcinoma via regulating KEAP1/Nrf2 signaling pathway. Anti-cancer drugs 34 (2) (2023)
Haipeng Huang, Jiange Zhang, Peng Jiang, Xiaolong Xu, Fu Huang, Binli Zhao, Xiaoming Wang, Liquan Zhou
FXR1 facilitates axitinib resistance in clear cell renal cell carcinoma via regulating KEAP1/Nrf2 signaling pathway. Anti-cancer drugs 34 (2) (2023)
Haipeng Huang, Jiange Zhang, Peng Jiang, Xiaolong Xu, Fu Huang, Binli Zhao, Xiaoming Wang, Liquan Zhou
FXR1 facilitates axitinib resistance in clear cell renal cell carcinoma via regulating KEAP1/Nrf2 signaling pathway. Anti-cancer drugs 34 (2) (2023)
Feng Yang, Quan-Fang Chen
A case of lung adenocarcinoma with MET∆ex14 mutation regressed after preoperative treatment with savolitinib, and successfully underwent radical resection. Anti-cancer drugs 34 (2) (2023)
Feng Yang, Quan-Fang Chen
A case of lung adenocarcinoma with MET∆ex14 mutation regressed after preoperative treatment with savolitinib, and successfully underwent radical resection. Anti-cancer drugs 34 (2) (2023)
Bingfeng Guan, Xiaofeng Dai, Yan Zhu, Qing Geng
M2 macrophage-derived exosomal miR-1911-5p promotes cell migration and invasion in lung adenocarcinoma by down-regulating CELF2 -activated ZBTB4 expression. Anti-cancer drugs 34 (2) (2023)
Feng Yang, Quan-Fang Chen
A case of lung adenocarcinoma with MET∆ex14 mutation regressed after preoperative treatment with savolitinib, and successfully underwent radical resection. Anti-cancer drugs 34 (2) (2023)

volume 34, number 4, 2023

Moustafa Salaheldin Abdelhamid, Ahmed Fouad El-Farargy, Omnia Abdelhai Esawi
Synthesis and evaluation of novel thiazole moiety-containing compounds as antibreast cancer agents. Anti-cancer drugs 34 (4) (2023)
Geena Chacko, Srigowri Kota, Shicha Kumar, Nisha Ohri, Coral Omene, Shridar Ganesan, Deborah L Toppmeyer, Mridula A George
Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer. Anti-cancer drugs 34 (4) (2023)
Geena Chacko, Srigowri Kota, Shicha Kumar, Nisha Ohri, Coral Omene, Shridar Ganesan, Deborah L Toppmeyer, Mridula A George
Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer. Anti-cancer drugs 34 (4) (2023)
Hima Patel, Rosalin Mishra, Adam Wier, Nazanin Mokhtarpour, Edward J Merino, Joan T Garrett
RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells. Anti-cancer drugs 34 (4) (2023)
Zhilin Gao, Yu Lian, Juanjuan Ti, Ruirui Ren, Liangming Ma
Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy. Anti-cancer drugs 34 (4) (2023)
Zachary A Bordeaux, Shawn G Kwatra, Laurence Booth, Paul Dent
A novel combination of isovanillin, curcumin, and harmine (GZ17-6.02) enhances cell death and alters signaling in actinic keratoses cells when compared to individual components and two-component combinations. Anti-cancer drugs 34 (4) (2023)
Zachary A Bordeaux, Shawn G Kwatra, Laurence Booth, Paul Dent
A novel combination of isovanillin, curcumin, and harmine (GZ17-6.02) enhances cell death and alters signaling in actinic keratoses cells when compared to individual components and two-component combinations. Anti-cancer drugs 34 (4) (2023)
Hima Patel, Rosalin Mishra, Adam Wier, Nazanin Mokhtarpour, Edward J Merino, Joan T Garrett
RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells. Anti-cancer drugs 34 (4) (2023)
Zhilin Gao, Yu Lian, Juanjuan Ti, Ruirui Ren, Liangming Ma
Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy. Anti-cancer drugs 34 (4) (2023)
Zachary A Bordeaux, Shawn G Kwatra, Laurence Booth, Paul Dent
A novel combination of isovanillin, curcumin, and harmine (GZ17-6.02) enhances cell death and alters signaling in actinic keratoses cells when compared to individual components and two-component combinations. Anti-cancer drugs 34 (4) (2023)
Zhilin Gao, Yu Lian, Juanjuan Ti, Ruirui Ren, Liangming Ma
Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy. Anti-cancer drugs 34 (4) (2023)
Moustafa Salaheldin Abdelhamid, Ahmed Fouad El-Farargy, Omnia Abdelhai Esawi
Synthesis and evaluation of novel thiazole moiety-containing compounds as antibreast cancer agents. Anti-cancer drugs 34 (4) (2023)
Hima Patel, Rosalin Mishra, Adam Wier, Nazanin Mokhtarpour, Edward J Merino, Joan T Garrett
RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells. Anti-cancer drugs 34 (4) (2023)
Geena Chacko, Srigowri Kota, Shicha Kumar, Nisha Ohri, Coral Omene, Shridar Ganesan, Deborah L Toppmeyer, Mridula A George
Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer. Anti-cancer drugs 34 (4) (2023)
Moustafa Salaheldin Abdelhamid, Ahmed Fouad El-Farargy, Omnia Abdelhai Esawi
Synthesis and evaluation of novel thiazole moiety-containing compounds as antibreast cancer agents. Anti-cancer drugs 34 (4) (2023)

volume 34, number 9, 2023

Laurence Booth, Andrew Poklepovic, John F Hancock, Paul Dent
Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells. Anti-cancer drugs 34 (9) (2023)